Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure

NCT05065957 is registered in ClinicalTrials.gov with InnoPharmax Inc. as lead sponsor.

NCT NCT05065957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure
Lead sponsor
InnoPharmax Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 29, 2022
Completion date
December 31, 2026
Enrollment
180 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer